Δ133p53 isoform enhances TLR4 function to promote tumour growth.

IF 2.9 3区 医学 Q2 ONCOLOGY
Sasini Polwatta Lekamlage, Alexandra N Boix De Jesus, Adriana Machado Saraiva, Catherine Drummond, Harrison Dolan, Francesc March de Ribot, Janice A Royds, Sunali Mehta, Antony W Braithwaite, Noelyn A Hung, Tania L Slatter
{"title":"Δ133p53 isoform enhances TLR4 function to promote tumour growth.","authors":"Sasini Polwatta Lekamlage, Alexandra N Boix De Jesus, Adriana Machado Saraiva, Catherine Drummond, Harrison Dolan, Francesc March de Ribot, Janice A Royds, Sunali Mehta, Antony W Braithwaite, Noelyn A Hung, Tania L Slatter","doi":"10.1093/carcin/bgaf051","DOIUrl":null,"url":null,"abstract":"<p><p>Tumour protein 53 (TP53) acts as a tumour suppressor and is often mutated in cancer. Isoforms of TP53, such as the Δ133p53 family, can promote tumour growth and metastasis. Therefore, targeting Δ133p53 function may represent a new strategy for preventing tumour metastasis. To inform the identification of proteins to target in Δ133p53-expressing tumours, changes at the cell surface were characterised. Inhibition of cell surface trafficking in a mouse model syngrafted with tumours expressing proteins similar to Δ133p53 (Δ122p53) was associated with reduced tumour growth and metastasis. After confirming that changes at the cell surface were important for Δ133p53 tumour promotion, characterisation of protein changes at the Δ133p53/Δ122p53 cell surface revealed increased expression of the toll-like receptor 4 (TLR4) and the TLR4 agonist, apoptosis inhibitor 5. Furthermore, inhibition of TLR4 was sufficient to reduce Δ122p53 tumour growth. Altogether, these results suggest a role for Δ133p53 in contributing to tumour progression by stimulating TLR4 function. Furthermore, targeting changes at the cell surface can reduce Δ133p53 tumour promotion.</p>","PeriodicalId":9446,"journal":{"name":"Carcinogenesis","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Carcinogenesis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/carcin/bgaf051","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumour protein 53 (TP53) acts as a tumour suppressor and is often mutated in cancer. Isoforms of TP53, such as the Δ133p53 family, can promote tumour growth and metastasis. Therefore, targeting Δ133p53 function may represent a new strategy for preventing tumour metastasis. To inform the identification of proteins to target in Δ133p53-expressing tumours, changes at the cell surface were characterised. Inhibition of cell surface trafficking in a mouse model syngrafted with tumours expressing proteins similar to Δ133p53 (Δ122p53) was associated with reduced tumour growth and metastasis. After confirming that changes at the cell surface were important for Δ133p53 tumour promotion, characterisation of protein changes at the Δ133p53/Δ122p53 cell surface revealed increased expression of the toll-like receptor 4 (TLR4) and the TLR4 agonist, apoptosis inhibitor 5. Furthermore, inhibition of TLR4 was sufficient to reduce Δ122p53 tumour growth. Altogether, these results suggest a role for Δ133p53 in contributing to tumour progression by stimulating TLR4 function. Furthermore, targeting changes at the cell surface can reduce Δ133p53 tumour promotion.

Δ133p53亚型增强TLR4功能,促进肿瘤生长。
肿瘤蛋白53 (TP53)作为肿瘤抑制因子,在癌症中经常发生突变。TP53的异构体,如Δ133p53家族,可以促进肿瘤的生长和转移。因此,靶向Δ133p53功能可能是一种预防肿瘤转移的新策略。为了确定Δ133p53-expressing肿瘤中的靶蛋白,对细胞表面的变化进行了表征。在与表达类似Δ133p53 (Δ122p53)蛋白的肿瘤共植的小鼠模型中,抑制细胞表面运输与肿瘤生长和转移的减少有关。在确认细胞表面的变化对Δ133p53肿瘤促进很重要之后,对Δ133p53/Δ122p53细胞表面蛋白变化的表征显示toll样受体4 (TLR4)和TLR4激动剂、细胞凋亡抑制剂5的表达增加。此外,抑制TLR4足以减少Δ122p53肿瘤生长。总之,这些结果表明Δ133p53通过刺激TLR4功能促进肿瘤进展。此外,靶向改变细胞表面可以减少Δ133p53肿瘤促进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Carcinogenesis
Carcinogenesis 医学-肿瘤学
CiteScore
9.20
自引率
2.10%
发文量
95
审稿时长
1 months
期刊介绍: Carcinogenesis: Integrative Cancer Research is a multi-disciplinary journal that brings together all the varied aspects of research that will ultimately lead to the prevention of cancer in man. The journal publishes papers that warrant prompt publication in the areas of Biology, Genetics and Epigenetics (including the processes of promotion, progression, signal transduction, apoptosis, genomic instability, growth factors, cell and molecular biology, mutation, DNA repair, genetics, etc.), Cancer Biomarkers and Molecular Epidemiology (including genetic predisposition to cancer, and epidemiology), Inflammation, Microenvironment and Prevention (including molecular dosimetry, chemoprevention, nutrition and cancer, etc.), and Carcinogenesis (including oncogenes and tumor suppressor genes in carcinogenesis, therapy resistance of solid tumors, cancer mouse models, apoptosis and senescence, novel therapeutic targets and cancer drugs).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信